search
Back to results

Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta

Primary Purpose

Osteogenesis Imperfecta

Status
Completed
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
standard-dose vitamin D (400IU per day)
high-dose vitamin D (2000 IU per day)
Sponsored by
Louis-Nicolas Veilleux Ph.D.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Osteogenesis Imperfecta focused on measuring osteogenesis imperfecta, high-dose vitamin D, bone density, muscle function

Eligibility Criteria

6 Years - 19 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of OI of any type.

Exclusion Criteria:

  • Any condition that renders bone density measurements at the lumbar spine impossible. An example for this is prior spinal fusion surgery.
  • Bisphosphonate therapy for less than two years duration.
  • Use of medication, other than bisphosphonates, known to affect bone metabolism or 25OHD serum concentrations. Examples are anti-epileptics, active vitamin D metabolites, corticosteroids and thyroid hormones.
  • Liver and renal disease known to interfere with vitamin D metabolism.
  • Any other disorder of calcium and phosphate metabolism (apart from vitamin D deficiency) that might interfere with PTH.

Sites / Locations

  • Shriners Hospitals for Children-Canada

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

standard-dose vitamin D

high-dose vitamin D

Arm Description

one group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group').

One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group').

Outcomes

Primary Outcome Measures

Change in areal bone mineral density z-score of the lumbar spine
LS-aBMD z-score will be used as the primary outcome.The lumbar spine is the standard site of measurement both in the clinical follow up of OI patients .

Secondary Outcome Measures

Change in trabecular and cortical volumetric bone mineral density z-scores at the radius, as measured by pQCT, relative to baseline.
Trabecular bone is analyzed at the distal radial metaphysis ('4% site'). Cortical bone is analyzed at the radial diaphysis ('65% site').

Full Information

First Posted
October 21, 2012
Last Updated
September 8, 2014
Sponsor
Louis-Nicolas Veilleux Ph.D.
search

1. Study Identification

Unique Protocol Identification Number
NCT01713231
Brief Title
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
Official Title
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
Study Type
Interventional

2. Study Status

Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
September 2012 (undefined)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
July 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Louis-Nicolas Veilleux Ph.D.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Overall Objective: To test the hypothesis that oral vitamin D supplementation at higher than currently prescribed doses has a beneficial effect on the skeleton of young patients with osteogenesis imperfecta (OI). Specific Aims: 1. To determine whether 12 months of high-dose vitamin D supplementation, compared to standard-dose vitamin D supplementation, increases areal bone mineral density z-scores at the lumbar spine. 2. To examine the effectiveness of high-dose vitamin D supplementation to increase trabecular and cortical bone mineral density at the radius. 3. To examine whether high-dose vitamin D supplementation has an effect on physiological determinants of bone mass (parathyroid hormone, activity of bone metabolism, muscle function). Background: In a preliminary cross-sectional study of 282 OI patients we observed an inverse relationship between serum 25-hydroxyvitamin D and parathyroid hormone levels and a positive relationship between circulating levels of 25-hydroxyvitamin D and lumbar spine areal bone mineral density z-scores. This suggested that high-dose vitamin D supplementation would have a beneficial effect on bone density. Most OI patients currently receive oral vitamin D supplementation of 400 International Units per day, but doses of 2000 International Units per day are safe and have been shown to be beneficial in studies on healthy adolescents. Study Design: This is a parallel-group double-blind randomized controlled trial of 12 months duration on 60 children and adolescents aged 6 to 19 years with a clinical diagnosis of OI. One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group'). The other group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group'). Randomization will be stratified according to pubertal status and bisphosphonate treatment status. Clinical Relevance: The proposed study aims at direct improvements in the care of OI patients. If a simple and low-cost 'intervention' such as high-dose vitamin D supplementation can be shown to be effective in relieving some of the disease burden associated with OI, the benefit to OI patients worldwide would be substantial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteogenesis Imperfecta
Keywords
osteogenesis imperfecta, high-dose vitamin D, bone density, muscle function

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
standard-dose vitamin D
Arm Type
Active Comparator
Arm Description
one group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group').
Arm Title
high-dose vitamin D
Arm Type
Experimental
Arm Description
One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group').
Intervention Type
Dietary Supplement
Intervention Name(s)
standard-dose vitamin D (400IU per day)
Intervention Type
Dietary Supplement
Intervention Name(s)
high-dose vitamin D (2000 IU per day)
Primary Outcome Measure Information:
Title
Change in areal bone mineral density z-score of the lumbar spine
Description
LS-aBMD z-score will be used as the primary outcome.The lumbar spine is the standard site of measurement both in the clinical follow up of OI patients .
Time Frame
at baseline and 12 months
Secondary Outcome Measure Information:
Title
Change in trabecular and cortical volumetric bone mineral density z-scores at the radius, as measured by pQCT, relative to baseline.
Description
Trabecular bone is analyzed at the distal radial metaphysis ('4% site'). Cortical bone is analyzed at the radial diaphysis ('65% site').
Time Frame
at baseline and at 12 months
Other Pre-specified Outcome Measures:
Title
Percentage change in lower extremity muscle power per body weight, as measured by jumping mechanography, relative to baseline.
Description
A countermovement jump to maximal height ('single two-legged jump') will be evaluated. In patients who are unable to jump, the heel-rise test will be used to determine muscle power.
Time Frame
baseline and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of OI of any type. Exclusion Criteria: Any condition that renders bone density measurements at the lumbar spine impossible. An example for this is prior spinal fusion surgery. Bisphosphonate therapy for less than two years duration. Use of medication, other than bisphosphonates, known to affect bone metabolism or 25OHD serum concentrations. Examples are anti-epileptics, active vitamin D metabolites, corticosteroids and thyroid hormones. Liver and renal disease known to interfere with vitamin D metabolism. Any other disorder of calcium and phosphate metabolism (apart from vitamin D deficiency) that might interfere with PTH.
Facility Information:
Facility Name
Shriners Hospitals for Children-Canada
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H3G1A6
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
26924265
Citation
Plante L, Veilleux LN, Glorieux FH, Weiler H, Rauch F. Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial. Bone. 2016 May;86:36-42. doi: 10.1016/j.bone.2016.02.013. Epub 2016 Feb 24.
Results Reference
derived

Learn more about this trial

Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta

We'll reach out to this number within 24 hrs